Celldex Therapeutics (CLDX) Retained Earnings (2010 - 2026)

Celldex Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 29.32% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 29.32% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, up 100.23% from the prior year.
• Retained Earnings fell to $2.5 million in Q1 2026 per CLDX's latest filing, from $3.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $5.3 million in Q3 2024 and bottomed at -$1.7 billion in Q3 2025.
• The 5-year median for Retained Earnings is -$417000.0 (2022), against an average of -$679.6 million.
• Biggest YoY gain for Retained Earnings was 1795.54% in 2023; the steepest drop was 315438.37% in 2023.
• Year by year, Retained Earnings stood at -$1.3 billion in 2022, then soared by 100.26% to $3.3 million in 2023, then slumped by 47114.03% to -$1.6 billion in 2024, then surged by 100.23% to $3.6 million in 2025, then tumbled by 30.45% to $2.5 million in 2026.
• Per Business Quant, the three latest CLDX Retained Earnings figures stand at $2.5 million (Q1 2026), $3.6 million (Q4 2025), and -$1.7 billion (Q3 2025).